You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 762 A first-in-human phase 1 clinical study evaluating safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the EDB+FN targeting ADC PYX-201 in participants with advanced solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
762 A first-in-human phase 1 clinical study evaluating safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the EDB+FN targeting ADC PYX-201 in participants with advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2023 to March 2026

AbstractFullPdf
Nov 2023214016
Dec 20235608
Jan 20248905
Feb 20248208
Mar 2024124010
Apr 202492010
May 202411007
Jun 20247607
Jul 202416609
Aug 20246204
Sep 202412207
Oct 2024154029
Nov 2024222047
Dec 2024102013
Jan 2025113012
Feb 202532017
Mar 2025209
Apr 20250012
May 2025006
Jun 2025008
Mar 2026002
Total18180246